On Tuesday, Novavx Inc said its COVID-19 vaccine has got emergency-use authorization from the Drug Controller General of India for 12-17 years children.
Novavax is manufactured and marketed in India by the Serum Institute of India under the name Covovax. Its vaccine authorization is a global first for the 12-17 years age group.
As per the trials conducted, Novavax is 80% effective against the virus. The testing was conducted on 2,247 teens between the age group of 12-17 years.
In a mid-to late-stage study involving 460 Indian adolescents, the company said its vaccine produced an immune response in the same age group
Following Biological E’s Corbevax, Zydus Cadila’s ZyCoV-D and Bharat Biotech’s Covaxin, Covovax is the fourth COVID-19 vaccine to be authorised for adolescents 12 years and older in India.
Last week, India began vaccinating children aged 12 to 14 with Biological E’s Corbevax, which had previously been given to children 15 and older. In December, the country’s drug regulator approved the COVID-19 vaccine for 18-year-olds and over.
